Introduction {#s1}
============

Coronary artery disease (CAD) is a major cause of death and disability in both developed and developing countries. Advancing age, male sex, hypertension, diabetes mellitus, dyslipidemia and cigarette smoking are the independent risk factors for CAD \[[@R01]\], but they do not entirely explain the variation in cardiovascular disease incidence and mortality. Therefore, additional risk factors have been proposed to better identify patients potentially at risk for CAD, and urinary albumin is a promising candidate. Since the first description in 1974 \[[@R02]\], the presence of subclinical increases in urinary albumin excretion (UAE) has attracted attention, but much remains to be understood about the role of microalbuminuria (MAU) in non-diabetic individuals.

An increasing number of studies in different patient populations have reported that MAU is independently associated with cardiovascular morbidity and mortality in patients with diabetes \[[@R03]\], hypertension \[[@R04]\] and in the general population \[[@R05]\]. On the contrary, some other studies have also shown that this correlation is independent of renal function, hypertension, and diabetes \[[@R06], [@R07]\]. Data from several studies have demonstrated that MAU predicts development of ischemic cardiovascular events related to the development of atherosclerosis \[[@R08]\]. MAU is a common phenomenon in patients with cardiovascular disease worldwide. The term MAU is defined as urinary albumin levels of more than or equal to 30 - 300 mg/24 h in 24-h urine collection or albumin/creatinine ratio (ACR) of \> 30 - 300 mg/g creatinine in random spot urine sample.

How MAU may be related to the development of atherosclerotic vascular disease is yet unclear. The currently accepted pathophysiological mechanism involves local injury to vascular smooth muscle cells and endothelium leading to cell proliferation and increase in vascular permeability \[[@R9], [@R10]\]. It is also reported that patients with MAU have a greater atherosclerosis burden in the form of multi-vessel CAD than in patients without it \[[@R11]\]. The association between albuminuria and cardiovascular events is well recognized \[[@R12]\], but few studies have addressed its correlation with the severity of CAD. This study was designed to investigate the relation between MAU, and the prevalence and severity of angiographically confirmed CAD in non-diabetic patients.

Materials and Methods {#s2}
=====================

Study population {#s2a}
----------------

The present cross-sectional study was done among enrolled non-diabetic patients who were suspected for CAD and who underwent elective coronary angiography at NEIGRIHMS, Meghalaya, India, between January 2014 and August 2015. A total of 90 patients were enrolled during study period. Coronary angiography and assessment of MAU were done at the same time. Exclusion criteria were: diabetes, recent history of acute myocardial infarction or percutaneous transluminal coronary angioplasty, congestive heart failure, malignant diseases, presence of active infection, renal failure, serum creatinine level over 2 mg/dL or glomerular filtration rate (GFR) below 30 dL/min, using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs). Initial evaluation of the patients by history and clinical examination were performed and recorded in the preformed data collection sheet. The data were collected on demographic and major cardiovascular risk factors including age, hypertension, diabetes mellitus, smoking and family history of CAD. Baseline laboratory investigations, e.g. complete blood count, chest roentgenogram, serum creatinine, serum electrolytes, fasting blood sugar, fasting lipid profile, electrocardiogram, and echocardiography, were done. Written consents were taken from all the patients. This study has been approved by institutional review committee and institute medical ethical committee.

Measurement of MAU {#s2b}
------------------

We collected a morning random urine sample before coronary artery catheterization. Urinary albumin concentration was measured by turbidimetric immunological technique, using Beckman Coulter AU 2700 auto-analyzer. Urine ACR was calculated and reported as mg/g creatinine. Patients with albumin levels less than 30 mg/g of creatinine were defined as having normoalbuminuria, those with albumin levels 30 - 300 mg/g as having MAU.

Coronary angiography (assessment for coronary artery atherosclerotic disease) {#s2c}
-----------------------------------------------------------------------------

The diagnostic procedure was performed by an experienced interventional cardiologist by using a Philips AlluraXper system via right femoral/right radial artery after performing local anesthesia with xylocaine. Interpretation of coronary angiogram was reviewed and angiographic severity of coronary artery disease was assessed by the number of vessels involved and SYNTAX score. The SYNTAX score is a tool to score complexity of CAD as follows: low (0 - 22), which is suitable for percutaneous coronary intervention (PCI), intermediate (23 - 32), which is suitable for either PCI or coronary artery bypass grafting (CABG), and high (≥ 33) where CABG is the preferred.

CAD was defined significant if there was ≥ 50% diameter stenosis in ≥ 1 major coronary artery.

Statistical analysis {#s2d}
--------------------

Data were statistically described in terms of median and interquartile range (IQR) for quantitative, while categorical variables were expressed as number and percentages when appropriate. Comparison between the study groups was done using Mann-Whitney U-test for numerical, Chi-square and Fisher's exact test for categorical data variables. Correlation between two numerical various variables was done using Pearson correlation coefficient (Spearman rho correlation coefficient equation for non-normal variables). P-values less than 0.05 were considered statistically significant. Statistical calculations were done using SPSS version 17.

Results {#s3}
=======

The study included 90 non-diabetic patients with documented CAD by elective coronary angiography. The patients were classified into two groups based on the presence or absence of MAU: group I (MAU negative) consisted of patients with ACR level \< 30 mg/g of creatinine (62 patients, 68.9%); group II (MAU positive) consisted of patients with ACR level 30 - 300 mg/g of creatinine (28 patients, 31.1%).

Demographic and clinical characteristics {#s3a}
----------------------------------------

Demographic and clinical characteristics of all patients are shown in [Table 1](#T1){ref-type="table"}. Among patients with a positive MAU test, the median age was 54 years. There were no significant differences in the prevalence of hypertension, hypercholesterolemia, smoking and family history of CAD between the two groups.

###### Demographic and Clinical Characteristics of Patients

  Variable                       Group I (MAU negative) (n = 62)   Group II (MAU positive) (n = 28)   P-value
  ------------------------------ --------------------------------- ---------------------------------- ---------
  Age (years)                    53 ± 3.25                         54 ± 2.75                          0.100
  Sex                                                                                                 0.994
    Males, n (%)                 40 (64.5%)                        19 (67.9%)                         
    Females, n (%)               22 (35.5%)                        9 (32.1% )                         
  Hypertension, n (%)            38 (61.2%)                        17 (60%)                           0.998
  Hypercholesterolemia, n (%)    22 (35.4%)                        10 (35.7%)                         0.513
  Smokers, n (%)                 21 (33.8%)                        9 (32.1%)                          0.999
  Family history of CAD, n (%)   7 (11.3%)                         3 (10.7%)                          0.999
  Fasting blood sugar (mg/dL)    86 ± 4                            85 ± 3.75                          0.499
  Serum creatinine (mg/dL)       1.07 ± 0.062                      1.08 ± 0.047                       0.254

Numerical data expressed as median ± IQR. CAD: coronary artery disease.

Prevalence of single vessel, double vessel and triple vessel CAD {#s3b}
----------------------------------------------------------------

The distribution of CAD severity in the groups with and without MAU is presented in [Table 2](#T2){ref-type="table"}. The prevalence of double vessel CAD and triple vessel CAD was significantly higher in MAU positive group. Double vessel CAD was present in 24.1% of patients in group I, whereas it was present in 46.4% of patients in group II (P = 0.033). Of patients, 42.8% and 12.9% in group II and group I had triple vessel CAD respectively (P = 0.002).

###### Prevalence of Single Vessel, Double Vessel and Triple Vessel CAD

  No. of vessel involved   Group I (MAU negative) (n = 62)   Group II (MAU positive) (n = 28)   P-value\*
  ------------------------ --------------------------------- ---------------------------------- -----------
  Single vessel, n (%)     39 (62.9%)                        3 (10.7%)                          \< 0.001
  Double vessel, n (%)     15 (24.1%)                        13 (46.4%)                         0.033
  Triple vessel, n (%)     8 (12.9%)                         12 (42.8%)                         0.002

\*P \< 0.05 was considered significant.

Correlation between MAU and severity of CAD (in terms of number of vessels involved) {#s3c}
------------------------------------------------------------------------------------

In group I, the correlation between MAU and severity of CAD was not statistically significant (r = - 0.035; P = 0.7850) ([Table 3](#T3){ref-type="table"}). On the other hand, presence of MAU exhibited a significant correlation with the severity of CAD (r = 0.094; P \< 0.001) ([Table 3](#T3){ref-type="table"}).

###### Correlation Between Microalbuminuria and Number of Vessels Affected

  Group                              SVD, n (%)   DVD, n (%)   TVD, n (%)   r\*; P-value
  ---------------------------------- ------------ ------------ ------------ ------------------------
  Group I (MAU negative) (n = 62)    39 (62.9%)   15 (24.1%)   8 (12.9%)    r = - 0.035; P = 0.785
  Group II (MAU positive) (n = 28)   3 (10.7%)    13 (46.4%)   12 (42.8%)   r = 0.094; P \< 0.001

MAU: microalbuminuria; CAD: coronary artery disease; SVD: single vessel disease; DVD: double vessel disease; TVD: triple vessel disease. r\* = Spearman rho correlation coefficient.

Median ACR level {#s3d}
----------------

The median ACR level in group I was 23 and in group II was 135.9 and this was statistically significant (P \< 0.001). Also, there was significant difference in the median of ACR level among patients with single vessel disease (SVD), double vessel disease (DVD) and triple vessel disease (TVD) in group II (121 vs. 131 vs. 146, P \< 0.001) ([Table 4](#T4){ref-type="table"}).

###### The Median ACR Level Among Patients With SVD, DVD and TVD in Group II

  Vessel affected   ACR level (median)   P-value
  ----------------- -------------------- -------------------------------------
  SVD               121                  \< 0.001 (between all comparison)\*
  DVD               131                  
  TVD               146                  

\*P \< 0.05 was considered significant. In all comparisons (SVD vs. DVD, SVD vs. TVD, DVD vs. TVD), P value was significant.

Relation between SYNTAX score and MAU {#s3e}
-------------------------------------

There was statistically significant difference between patients with and those without MAU regarding their SYNTAX scores. Patients with MAU had higher SYNTAX scores compared to those without MAU (28 ± 8 vs. 21 ± 6, P \< 0.001), as shown in [Table 5](#T5){ref-type="table"}.

###### Median SYNTAX Score Between the Two Groups

                                     SYNTAX score, median ± IQR   P-value
  ---------------------------------- ---------------------------- ----------
  Group I (MAU negative) (n = 62)    21 ± 6                       \< 0.001
  Group II (MAU positive) (n = 28)   28 ± 8                       

MAU: microalbuminuria; IQR: interquartile range. P \< 0.05 was considered significant.

In both groups, the severity of CAD by SYNTAX score was evaluated as low score ≤ 22 and intermediate or high score \> 22. In group I, 45 patients (72.5%) had a low SYNTAX score ≤ 22 and 17 patients (27.4%) had an intermediate or high score \> 22. In group II, six patients (21.4%) had a low SYNTAX score ≤ 22 and 22 patients (78.5%) had an intermediate or high score \> 22 ([Table 6](#T6){ref-type="table"}).

###### Relation Between SYNTAX Score and ACR

  Urinary ACR   SYNTAX ≤ 22, n (%)   SYNTAX \> 22, n (%)   P-value
  ------------- -------------------- --------------------- ------------------------
  Group I       45 (72.5%)           17 (27.4%)            \< 0.001 (both groups)
  Group II      6 (21.4%)            22 (78.5%)            

ACR: albumin/creatinine ratio. P \< 0.05 was considered significant. Also, when group I and group II where compared, patients with MAU had higher SYNTAX scores compared to those without MAU (P \< 0.001).

Discussion {#s4}
==========

Albumin excretion in the range of 30 - 300 mg/g of urinary creatinine is referred to as MAU. In the present study urinary ACR in spot urine sample was used to detect MAU, as it was shown to be equally sensitive and specific to 24-h urine collection method \[[@R13]\]. MAU is highly prevalent in several disease states. In this study, we found that the frequency of MAU was elevated in the study population (31.1%) which is significantly higher as compared to the general population which ranges from 5% to 7% in previous studies \[[@R14], [@R15]\]. Thus this study highlights that MAU is more frequent in non-diabetic patients with CAD than the general population and may be an important emerging risk marker for CAD. In the present study, there were no significant differences in the prevalence of hypertension, hypercholesterolemia, smoking and family history of CAD between the two groups. Differing from Gou et al \[[@R16]\], we did not find any relation between MAU with, hypercholesterolemia, cigarette smoking and hypertension. Although previous studies have reported the association between hypertension and MAU \[[@R17], [@R18]\], in the present investigation, we were not able to see a similar association. This diversity could be due to differences in sample size, race and geographic or nutritional factors.

The prevalence of double vessel CAD and triple vessel CAD was significantly higher in MAU positive group. The current study showed that patients with MAU have a greater atherosclerotic burden and a more severe CAD in the form of total number of vessels affected per patient than those without MAU. The results are in accordance with the previously reported findings \[[@R19]-[@R22]\]. In the present study, presence of MAU exhibited a significant correlation with the severity of CAD (r = 0.094; P \< 0.001). Previous studies by Guo et al \[[@R16]\], Hoseini et al \[[@R21]\], and Al Saffar et al \[[@R22]\] also concluded that there was a positive correlation between severity of CAD and MAU in non-diabetic patients. The median ACR level in group I was 23 and in group II was 135.9 and this was statistically significant (P \< 0.001). Hashim et al \[[@R20]\] in their study found a mean ACR of 131.8 ± 66.2 mg/g. In the present study, patients with MAU had higher SYNTAX scores compared to those without MAU (28 ± 8 vs. 21 ± 6, P \< 0.001), showing that presence of MAU was associated with more complex CAD. This finding was in agreement with previous reports \[[@R19], [@R23]\]. The mechanism whereby MAU accelerates atherosclerosis is unclear. It is proposed that MAU indicates early and possibly reversible glomerular damage \[[@R04]\]. In non-diabetic persons with MAU, alterations in the extracellular matrix cause an increase in vascular permeability and this contributes to the development of endothelial dysfunction which promotes lipid influx into the vessel wall causing atherosclerotic changes \[[@R24]\]. It appears that aggressive treatment of MAU is beneficial in CAD patients. Several strategies are available to lower UAE. Widely known is the albuminuria-lowering effect of antihypertensive agents, which intervene with the renin angiotensin-aldosterone system. Ibsen et al \[[@R25]\] showed that a decrease in baseline albuminuria, which was more significant with losartan than with atenolol, results in significant reduction in cardiovascular events. Asselbergs et al \[[@R26]\] showed that the lowering of albuminuria with the ACEI fosinopril tended to be cardioprotective.

Gosling et al \[[@R27]\] and Haffner et al \[[@R28]\] considered MAU as an emerging cardiovascular risk factor in the non-diabetic patients. The present study agrees with these observations as it shows a significant MAU in non-diabetic CAD patients. This study has some limitations. First, it is a cross-sectional study, so a causal relationship cannot be established. Second, it is a single center study, with a small number of patients.

Conclusion {#s4a}
----------

In our study, we found significantly high MAU levels in non-diabetic patients. The results of the present study indicate that non-diabetic patients with MAU have more extensive and complex angiographic CAD compared to those without MAU. Since the MAU is simple and relatively inexpensive investigation, early identification of MAU may influence the aggressiveness of management and ultimately the outcome of the disease.
